Clinical and pharmacological group: & nbsp

Metabolics

Included in the formulation
  • Corilip
    suppositories rect. 
    ALTFARM, LLC     Russia
  • Corilip-Neo
    suppositories rect. 
    ALTFARM, LLC     Russia
  • АТХ:

    A.11.E.X   B group vitamins in combination with other drugs

    Pharmacodynamics:

    Kokarboksilaza - coenzyme, formed in the body of thiamine. Has a metabolic action, activates tissue metabolism. In the body it is phosphorylated to form mono-, di- and triphosphoric esters; is part of the enzymes that catalyze the carboxylation and decarboxylation of keto acids, pyruvic acid, promotes the formation of acetyl-coenzyme A, which determines its participation in carbohydrate metabolism. Participation in the pentose cycle indirectly promotes the synthesis of nucleic acids, proteins and lipids.

    Improves the absorption of glucose, trophic nervous tissue, contributes to the normalization of the functions of the cardiovascular system.

    Cocarboxylase deficiency causes an increase in the level of pyruvic acid and lactic acid in the blood, which leads to metabolic acidosis.

    In the body, vitamin B2 (medicine - riboflavin) Is phosphorylated, becoming a coenzyme - flavin mononucleotide and flavin adenine dinucleotide involved in carbohydrate, protein, fat metabolism, tissue respiration, blood formation. Riboflavin deficiency appear photophobia, pain in the eyes. Vitamin AT2 maintains the normal state of the mucous membrane of the digestive tract, lips and tongue, is necessary for absorption of iron, the formation of nicotinic acid, the activation of the vitamin AT6.

    Thioctic acid - coenzyme, involved in the oxidative decarboxylation of pyruvic acid and α-keto acids, improves the energy metabolism of hepatocytes. Refers to hepatotropic drugs.

    Pharmacokinetics:

    Not studied.

    Indications:

    Chronic tissue hypoxia, decreased immunity (bacterial and viral infections), chronic somatic diseases, chronic intoxication, condition after severe illnesses, nutritional disorders (hypotrophy). Periods of intensive growth and development of new functions in the child, intense physical and mental stress, stress. Prevention during the epidemic of infectious diseases.

    XXI.Z80-Z99.Z86.1   In a personal anamnesis, infectious and parasitic diseases

    XXI.Z20-Z29.Z26.9   The need for immunization against unspecified infectious disease

    XXI.Z20-Z29.Z22.9   Carrying out the causative agent of infectious disease, unspecified

    XXI.Z20-Z29.Z22   Carrying out the causative agent of infectious disease

    XV.O95-O99.O98.9   Infectious and parasitic diseases of the mother complicating pregnancy, childbirth or the puerperium, unspecified

    I.B99.B99   Other and unspecified infectious diseases

    I.B99   Other infectious diseases

    I   Some infectious and parasitic diseases

    XXI.Z70-Z76.Z73.3   Stress condition, not elsewhere classified

    XXI.Z55-Z65.Z63.7   Other stressful life events that affect the family and economic conditions

    XVIII.R40-R46.R45.7   Condition of emotional shock and stress, unspecified

    V.F40-F48.F43.9   Reaction to severe stress, unspecified

    V.F40-F48.F43.8   Other reactions to severe stress

    V.F40-F48.F43.0   Acute stress reaction

    V.F40-F48.F43   Reaction to severe stress and adaptation disorders

    XXI.Z40-Z54.Z54.9   Condition of recovery after unspecified type of treatment

    XXI.Z40-Z54.Z54.8   The state of recovery after other treatment

    XXI.Z40-Z54.Z54.7   The state of recovery after combined treatment

    XXI.Z40-Z54.Z54.2   Condition of recovery after chemotherapy

    XXI.Z40-Z54.Z54.1   Condition of recovery after radiotherapy

    XXI.Z40-Z54.Z54.0   Condition of recovery after surgery

    XXI.Z40-Z54.Z54   Condition of recovery

    Contraindications:Hypersensitivity.
    Carefully:

    No data.

    Pregnancy and lactation:

    The FDA recommendation category is C.

    The use of the drug is acceptable in pregnancy and during breastfeeding, if necessary.

    Dosing and Administration:

    Rectal. Dosage for newborns and infants is 1/2 suppository per day; children of early and preschool age (from 1 year to 6 years) - 1 suppository per day; children from 6 to 14 years - 1-2 suppositories per day.

    The duration of the course of treatment is 10 days. The total duration of treatment is 3-4 courses with an interval of 20 days (3-4 months).

    Side effects:

    Possible: allergic reactions (hives, itching).

    With intramuscular injection: possible hyperemia, itching, swelling at the injection site.

    Overdose:

    Not described.

    Interaction:

    Strengthens cardiotonic action of cardiac glycosides and improves their tolerability.

    Special instructions:

    Criteria for the duration of treatment along with the clinical status are the cytochemical indices of the activity of peripheral blood leukocyte enzymes (succinate dehydrogenase and glycerophosphate dehydrogenase).

    Instructions
    Up